Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Stake Increased by Allianz SE

Key Points

• Allianz SE increased its stake in Genenta Science S.p.A. by 126.2%, acquiring an additional 130,300 shares to own a total of 233,550 shares, valued at approximately $927,000.
• Algebris UK Ltd also raised its investment in Genenta Science by 122.2%, now owning 100,000 shares worth $368,000 after purchasing 55,000 shares.
• Genenta Science's stock is currently trading at $3.73 with a 52-week range between $2.74 and $7.28.

Allianz SE increased its stake in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA - Free Report) by 126.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,550 shares of the company's stock after purchasing an additional 130,300 shares during the quarter. Allianz SE owned approximately 1.28% of Genenta Science worth $927,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Citadel Advisors LLC acquired a new position in Genenta Science during the 4th quarter worth approximately $46,000. Institutional investors own 15.13% of the company's stock.

Genenta Science Price Performance

GNTA traded down $0.05 during trading hours on Friday, reaching $3.75. 553 shares of the stock traded hands, compared to its average volume of 15,371. The firm's fifty day simple moving average is $3.78 and its two-hundred day simple moving average is $3.91. Genenta Science S.p.A. Unsponsored ADR has a fifty-two week low of $2.74 and a fifty-two week high of $7.28.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.